Source comparison
Tesamorelin + Ipamorelin Blend Alternatives 2026 Best: Receptor Mechanisms and Half-Life Comparison
| Compound | Primary Receptor Target | Plasma Half-Life | GH Pulse Amplitude (relative to ipamorelin) | Cortisol/Prolactin Elevation | Dosing Frequency | Bottom Line ||—|—|—|—|—|—|| Tesamorelin/Ipamorelin Blend | GHRH-R + GHSR1a | 26–38 min / 2 hr | 1.0× (base
This comparison does not assign a generated winner or score.
- | Compound | Primary Receptor Target | Plasma Half-Life | GH Pulse Amplitude (relative to ipamorelin) | Cortisol/Prolactin Elevation | Dosing Frequency | Bottom Line ||—|—|—|—|—|—|| Tesamorelin/Ipamorelin Blend | GHRH-R + GHSR1a | 26–38 min / 2 hr | 1.0× (baseline) | Minimal (ipamorelin selective) | Twice daily, timed 15–20 min apart | Effective but coordination-intensive; best when precise GH pulse timing is the study endpoint || CJC-1295/Ipamorelin | GHRH-R + GHSR1a | 6–8 days / 2 hr | 1.1–1.3× | Minimal | CJC weekly, ipamorelin daily or twice daily | Superior for multi-week protocols; eliminates timing errors and maintains stable GHRH pathway activity || Hexarelin | GHSR1a + CD36 receptor | 70–90 min | 1.4–1.6× | Moderate (dose-dependent cortisol spike) | Once or twice daily | Highest GH pulse amplitude; unsuitable when cortisol/prolactin confounds are unacceptable || GHRP-2 | GHSR1a | 20–30 min | 1.2–1.3× | Low (10–15% cortisol elevation) | Twice daily | Clean middle option; larger